Tumor expression of calcium sensing receptor and colorectal cancer survival: Results from the nurses’ health study and health professionals follow-up study

Fatemeh Momen-Heravi, Yohei Masugi, Zhi Rong Qian, Reiko Nishihara, Li Liu, Stephanie A. Smith-Warner, Na Na Keum, Lanjing Zhang, Nairi Tchrakian, Jonathan A. Nowak, Wanshui Yang, Yanan Ma, Michaela Bowden, Annacarolina da Silva, Molin Wang, Charles S. Fuchs, Jeffrey A. Meyerhardt, Kimmie Ng, Kana Wu, Edward GiovannucciShuji Ogino, Xuehong Zhang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Although experimental evidence suggests calcium-sensing receptor (CASR) as a tumor-suppressor, the prognostic role of tumor CASR expression in colorectal carcinoma remains unclear. We hypothesized that higher tumor CASR expression might be associated with improved survival among colorectal cancer patients. We evaluated tumor expression levels of CASR by immunohistochemistry in 809 incident colorectal cancer patients within the Nurses' Health Study and the Health Professionals Follow-up Study. We used Cox proportional hazards regression models to estimate multivariable hazard ratio (HR) for the association of tumor CASR expression with colorectal cancer-specific and all-cause mortality. We adjusted for potential confounders including tumor biomarkers such as microsatellite instability, CpG island methylator phenotype, LINE-1 methylation level, expressions of PTGS2, VDR and CTNNB1 and mutations of KRAS, BRAF and PIK3CA. There were 240 colorectal cancer-specific deaths and 427 all-cause deaths. The median follow-up of censored patients was 10.8 years (interquartile range: 7.2, 15.1). Compared with patients with no or weak expression of CASR, the multivariable HRs for colorectal cancer-specific mortality were 0.80 [95% confidence interval (CI): 0.55–1.16] in patients with moderate CASR expression and 0.50 (95% CI: 0.32–0.79) in patients with intense CASR expression (p-trend = 0.003). The corresponding HRs for overall mortality were 0.85 (0.64–1.13) and 0.81 (0.58–1.12), respectively. Higher tumor CASR expression was associated with a lower risk of colorectal cancer-specific mortality. This finding needs further confirmation and if confirmed, may lead to better understanding of the role of CASR in colorectal cancer progression.

Original languageEnglish
Pages (from-to)2471-2479
Number of pages9
JournalInternational Journal of Cancer
Volume141
Issue number12
DOIs
Publication statusPublished - 2017 Dec 15
Externally publishedYes

Fingerprint

Calcium-Sensing Receptors
Colorectal Neoplasms
Nurses
Survival
Health
Neoplasms
Mortality
Confidence Intervals
Microsatellite Instability
CpG Islands
Cyclooxygenase 2
Tumor Biomarkers
Proportional Hazards Models
Methylation
Cause of Death
Immunohistochemistry
Phenotype

Keywords

  • calcium
  • calcium sensing receptor
  • colorectal cancer
  • molecular pathological epidemiology
  • progression
  • prospective cohorts
  • survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Tumor expression of calcium sensing receptor and colorectal cancer survival : Results from the nurses’ health study and health professionals follow-up study. / Momen-Heravi, Fatemeh; Masugi, Yohei; Qian, Zhi Rong; Nishihara, Reiko; Liu, Li; Smith-Warner, Stephanie A.; Keum, Na Na; Zhang, Lanjing; Tchrakian, Nairi; Nowak, Jonathan A.; Yang, Wanshui; Ma, Yanan; Bowden, Michaela; da Silva, Annacarolina; Wang, Molin; Fuchs, Charles S.; Meyerhardt, Jeffrey A.; Ng, Kimmie; Wu, Kana; Giovannucci, Edward; Ogino, Shuji; Zhang, Xuehong.

In: International Journal of Cancer, Vol. 141, No. 12, 15.12.2017, p. 2471-2479.

Research output: Contribution to journalArticle

Momen-Heravi, F, Masugi, Y, Qian, ZR, Nishihara, R, Liu, L, Smith-Warner, SA, Keum, NN, Zhang, L, Tchrakian, N, Nowak, JA, Yang, W, Ma, Y, Bowden, M, da Silva, A, Wang, M, Fuchs, CS, Meyerhardt, JA, Ng, K, Wu, K, Giovannucci, E, Ogino, S & Zhang, X 2017, 'Tumor expression of calcium sensing receptor and colorectal cancer survival: Results from the nurses’ health study and health professionals follow-up study', International Journal of Cancer, vol. 141, no. 12, pp. 2471-2479. https://doi.org/10.1002/ijc.31021
Momen-Heravi, Fatemeh ; Masugi, Yohei ; Qian, Zhi Rong ; Nishihara, Reiko ; Liu, Li ; Smith-Warner, Stephanie A. ; Keum, Na Na ; Zhang, Lanjing ; Tchrakian, Nairi ; Nowak, Jonathan A. ; Yang, Wanshui ; Ma, Yanan ; Bowden, Michaela ; da Silva, Annacarolina ; Wang, Molin ; Fuchs, Charles S. ; Meyerhardt, Jeffrey A. ; Ng, Kimmie ; Wu, Kana ; Giovannucci, Edward ; Ogino, Shuji ; Zhang, Xuehong. / Tumor expression of calcium sensing receptor and colorectal cancer survival : Results from the nurses’ health study and health professionals follow-up study. In: International Journal of Cancer. 2017 ; Vol. 141, No. 12. pp. 2471-2479.
@article{1d4cbd89c71a43ad8f71ed3df3f66910,
title = "Tumor expression of calcium sensing receptor and colorectal cancer survival: Results from the nurses’ health study and health professionals follow-up study",
abstract = "Although experimental evidence suggests calcium-sensing receptor (CASR) as a tumor-suppressor, the prognostic role of tumor CASR expression in colorectal carcinoma remains unclear. We hypothesized that higher tumor CASR expression might be associated with improved survival among colorectal cancer patients. We evaluated tumor expression levels of CASR by immunohistochemistry in 809 incident colorectal cancer patients within the Nurses' Health Study and the Health Professionals Follow-up Study. We used Cox proportional hazards regression models to estimate multivariable hazard ratio (HR) for the association of tumor CASR expression with colorectal cancer-specific and all-cause mortality. We adjusted for potential confounders including tumor biomarkers such as microsatellite instability, CpG island methylator phenotype, LINE-1 methylation level, expressions of PTGS2, VDR and CTNNB1 and mutations of KRAS, BRAF and PIK3CA. There were 240 colorectal cancer-specific deaths and 427 all-cause deaths. The median follow-up of censored patients was 10.8 years (interquartile range: 7.2, 15.1). Compared with patients with no or weak expression of CASR, the multivariable HRs for colorectal cancer-specific mortality were 0.80 [95{\%} confidence interval (CI): 0.55–1.16] in patients with moderate CASR expression and 0.50 (95{\%} CI: 0.32–0.79) in patients with intense CASR expression (p-trend = 0.003). The corresponding HRs for overall mortality were 0.85 (0.64–1.13) and 0.81 (0.58–1.12), respectively. Higher tumor CASR expression was associated with a lower risk of colorectal cancer-specific mortality. This finding needs further confirmation and if confirmed, may lead to better understanding of the role of CASR in colorectal cancer progression.",
keywords = "calcium, calcium sensing receptor, colorectal cancer, molecular pathological epidemiology, progression, prospective cohorts, survival",
author = "Fatemeh Momen-Heravi and Yohei Masugi and Qian, {Zhi Rong} and Reiko Nishihara and Li Liu and Smith-Warner, {Stephanie A.} and Keum, {Na Na} and Lanjing Zhang and Nairi Tchrakian and Nowak, {Jonathan A.} and Wanshui Yang and Yanan Ma and Michaela Bowden and {da Silva}, Annacarolina and Molin Wang and Fuchs, {Charles S.} and Meyerhardt, {Jeffrey A.} and Kimmie Ng and Kana Wu and Edward Giovannucci and Shuji Ogino and Xuehong Zhang",
year = "2017",
month = "12",
day = "15",
doi = "10.1002/ijc.31021",
language = "English",
volume = "141",
pages = "2471--2479",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - Tumor expression of calcium sensing receptor and colorectal cancer survival

T2 - Results from the nurses’ health study and health professionals follow-up study

AU - Momen-Heravi, Fatemeh

AU - Masugi, Yohei

AU - Qian, Zhi Rong

AU - Nishihara, Reiko

AU - Liu, Li

AU - Smith-Warner, Stephanie A.

AU - Keum, Na Na

AU - Zhang, Lanjing

AU - Tchrakian, Nairi

AU - Nowak, Jonathan A.

AU - Yang, Wanshui

AU - Ma, Yanan

AU - Bowden, Michaela

AU - da Silva, Annacarolina

AU - Wang, Molin

AU - Fuchs, Charles S.

AU - Meyerhardt, Jeffrey A.

AU - Ng, Kimmie

AU - Wu, Kana

AU - Giovannucci, Edward

AU - Ogino, Shuji

AU - Zhang, Xuehong

PY - 2017/12/15

Y1 - 2017/12/15

N2 - Although experimental evidence suggests calcium-sensing receptor (CASR) as a tumor-suppressor, the prognostic role of tumor CASR expression in colorectal carcinoma remains unclear. We hypothesized that higher tumor CASR expression might be associated with improved survival among colorectal cancer patients. We evaluated tumor expression levels of CASR by immunohistochemistry in 809 incident colorectal cancer patients within the Nurses' Health Study and the Health Professionals Follow-up Study. We used Cox proportional hazards regression models to estimate multivariable hazard ratio (HR) for the association of tumor CASR expression with colorectal cancer-specific and all-cause mortality. We adjusted for potential confounders including tumor biomarkers such as microsatellite instability, CpG island methylator phenotype, LINE-1 methylation level, expressions of PTGS2, VDR and CTNNB1 and mutations of KRAS, BRAF and PIK3CA. There were 240 colorectal cancer-specific deaths and 427 all-cause deaths. The median follow-up of censored patients was 10.8 years (interquartile range: 7.2, 15.1). Compared with patients with no or weak expression of CASR, the multivariable HRs for colorectal cancer-specific mortality were 0.80 [95% confidence interval (CI): 0.55–1.16] in patients with moderate CASR expression and 0.50 (95% CI: 0.32–0.79) in patients with intense CASR expression (p-trend = 0.003). The corresponding HRs for overall mortality were 0.85 (0.64–1.13) and 0.81 (0.58–1.12), respectively. Higher tumor CASR expression was associated with a lower risk of colorectal cancer-specific mortality. This finding needs further confirmation and if confirmed, may lead to better understanding of the role of CASR in colorectal cancer progression.

AB - Although experimental evidence suggests calcium-sensing receptor (CASR) as a tumor-suppressor, the prognostic role of tumor CASR expression in colorectal carcinoma remains unclear. We hypothesized that higher tumor CASR expression might be associated with improved survival among colorectal cancer patients. We evaluated tumor expression levels of CASR by immunohistochemistry in 809 incident colorectal cancer patients within the Nurses' Health Study and the Health Professionals Follow-up Study. We used Cox proportional hazards regression models to estimate multivariable hazard ratio (HR) for the association of tumor CASR expression with colorectal cancer-specific and all-cause mortality. We adjusted for potential confounders including tumor biomarkers such as microsatellite instability, CpG island methylator phenotype, LINE-1 methylation level, expressions of PTGS2, VDR and CTNNB1 and mutations of KRAS, BRAF and PIK3CA. There were 240 colorectal cancer-specific deaths and 427 all-cause deaths. The median follow-up of censored patients was 10.8 years (interquartile range: 7.2, 15.1). Compared with patients with no or weak expression of CASR, the multivariable HRs for colorectal cancer-specific mortality were 0.80 [95% confidence interval (CI): 0.55–1.16] in patients with moderate CASR expression and 0.50 (95% CI: 0.32–0.79) in patients with intense CASR expression (p-trend = 0.003). The corresponding HRs for overall mortality were 0.85 (0.64–1.13) and 0.81 (0.58–1.12), respectively. Higher tumor CASR expression was associated with a lower risk of colorectal cancer-specific mortality. This finding needs further confirmation and if confirmed, may lead to better understanding of the role of CASR in colorectal cancer progression.

KW - calcium

KW - calcium sensing receptor

KW - colorectal cancer

KW - molecular pathological epidemiology

KW - progression

KW - prospective cohorts

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85030174396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030174396&partnerID=8YFLogxK

U2 - 10.1002/ijc.31021

DO - 10.1002/ijc.31021

M3 - Article

C2 - 28856682

AN - SCOPUS:85030174396

VL - 141

SP - 2471

EP - 2479

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 12

ER -